• Friday, October 21, 2022 @ 7:00 am

Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, is pleased to announce the recent launch of Octasa 800mg (mesalazine) delayed-release tablets, as first-line treatment for moderately active ulcerative colitis (UC) in Canada.

The launch of Octasa 800mg represents an important step in Tillotts’ strategic partnership with Pendopharm, Division of Pharmascience Inc. Canada and a milestone for both organisations.

Canada has one of the highest incidences of ulcerative colitis in the world, with 7 in 1,000 Canadians affected by the disease. By 2030, the incidence of UC in Canada is expected to rise to 1% or 1 in 100 (403,000 Canadians).[1]

The introduction of Octasa 800mg (mesalazine) delayed-release tablets to the Canadian market is expected to optimise the therapeutic options for Inflammatory Bowel Disease (IBD) in Canada.

Adrian Hill, Global Head of Commercial Operations at Tillotts, said: “We are very excited to announce that Octasa 800mg from Tillotts AG is now available in Canada. The commercial launch of Octasa 800mg tablets in Canada will bring a new treatment option in the form of a tablet to clinicians and patients. This has been achieved through the strong strategic partnership between Tillotts and Pendopharm.”

Jad Isber, Vice President and General Manager at Pendopharm, added: "We are delighted to continue our strong relationship with Tillotts by bringing Octasa 800mg to Canadian patients suffering from moderately active ulcerative colitis. The addition of Octasa 800mg to our portfolio will further enhance Pendopharm’s leadership position in GI, bringing a new treatment option to healthcare professionals and patients."

[1] https://crohnsandcolitis.ca/About-Us/Resources-Publications/Impact-of-IBD-Report

You may also be interested in